If you're looking for under-the-radar stocks to buy, there's no better place to start your search than the biotech industry. Hardly a week goes by without at least one new biotechnology company going public.
BridgeBio Pharma (NASDAQ: BBIO) is a member of the IPO class of 2019 that takes a unique approach to the business of drug development. Axovant Gene Therapies (NASDAQ: AXGT) has been around for much longer, but it has a relatively strong candidate for the treatment of Parkinson's disease that's meant to provide a lifelong benefit with just one shot. Both of these biotechs deserve a lot more attention than they've been receiving.
Image source: Getty Images.
For further details see:
2 Under-the-Radar Biotech Stocks You'll Wish You Didn't Ignore